Show simple item record

dc.contributor.authorCagatay, Penbe
dc.contributor.authorSÜSLEYİCİ, BELGİN
dc.contributor.authorAtas, Halil
dc.contributor.authorCiftci, Cavlan
dc.contributor.authorKARAALP, ATİLA
dc.contributor.authorBezci, Kivanc
dc.contributor.authorCevik, Mehtap
dc.contributor.authorAkdeniz, Cansu Selcan
dc.contributor.authorCanbolat, Ismail Polat
dc.contributor.authorYurdakul, Selen
dc.contributor.authorSÜNBÜL, MURAT
dc.date.accessioned2021-03-02T17:19:47Z
dc.date.available2021-03-02T17:19:47Z
dc.identifier.citationBezci K., Cevik M., Akdeniz C. S. , Canbolat I. P. , Yurdakul S., SÜNBÜL M., Atas H., Cagatay P., Ciftci C., KARAALP A., et al., "Warfarin pharmacogenetics in patients with heart valve replacement", GENE REPORTS, cilt.20, 2020
dc.identifier.othervv_1032021
dc.identifier.otherav_743bb929-c6df-4aab-9159-0de6ab82e243
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3684
dc.identifier.urihttps://doi.org/10.1016/j.genrep.2020.100769
dc.description.abstractBackground: Warfarin treatment is crucial to prevent thrombolytic complications after the heart valve replacement (HVR) operation. Our purpose was to investigate the prevalence of CYP2C9 *2 and *3 gene polymorphisms, which are essential in warfarin metabolism in patients with and without HVR surgery prescribed with warfarin.
dc.language.isoeng
dc.subjectTıbbi Genetik
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectTemel Bilimler
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectGENETİK VE HAYAT
dc.titleWarfarin pharmacogenetics in patients with heart valve replacement
dc.typeMakale
dc.relation.journalGENE REPORTS
dc.contributor.departmentMarmara Üniversitesi , ,
dc.identifier.volume20
dc.contributor.firstauthorID2286704


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record